Citing insufficient evidence of medicinal benefits and potential for harm, the move to ban CBD has the potential to put the brakes on reform in the region.
Yimsaard et al. note that Thailand's public health impact of cannabis legalisation must be carefully monitored and underline the necessity for evidence-based guidelines to inform prevention strategies, and implement interventions for at-risk populations, including young adults.
IDPC addresses the tensions facing the INCB, and the global drug control regime as a whole, in relation to the increasing number of jurisdictions adopting legally regulated markets, and concludes on the need for reform and modernisation.
Despite attempts by the outgoing administration to ban the prescription of cannabis products, a growing number of activists, civil society, health professionals and politicians mobilise to secure safe access.
Craft et al. find no clear evidence that exposure to analytically confirmed synthetic cannabinoids increased or decreased after implementing the Psychoactive Substances Act 2016.
The Penington Institute discusses medicinal access, reducing the harms associated with current laws and substance use, and ideas towards more compassionate frameworks.
Dejusticia argues for the importance of a fiscal framework with a focus on financing the goals of reducing the illegal market, preserving public health and assisting populations affected by drug policy.
